Bayer
This article was originally published in The Tan Sheet
Executive Summary
Print ad in the June 17 New England Journal of Medicine for enteric-coated Bayer aspirin states, "Aspirin should be at the core of prevention. So why aren't more patients on aspirin?" Despite evidence that "aspirin-based therapy reduces vascular events among a broad range of at-risk patients...recent clinical studies and expanded FDA indications, millions of patients for whom aspirin may be appropriate still don't take it as part of their prevention regimen," the ad notes. "No other prevention medication is as affordable as aspirin," the ad concludes